Bristol Myers Squibb will work with PathAI in the fields of oncology, fibrosis and immunology. The partnership will use AI models to better identify patient populations, according to an Aug. 25 PathAI news release.
“Given the insights generated from past collaborations, we have entered into a long-term collaboration with Bristol Myers Squibb to expand our use of machine learning models,” PathAI CEO and co-founder Andy Beck, MD, PhD, said in the release. “We will build on our work using AI-based pathology in translational research and validate the use of this technology through clinical trials and diagnostic development.”
